Can lamotrigine be prescribed to a patient with congenital heart disease?

Can Lamotrigine Be Used in Someone with a Congenital Heart Defect?

Yes, lamotrigine can be used in patients with congenital heart disease, as there is no specific contraindication and no evidence of increased cardiac morbidity or mortality in this population. However, monitoring for modest PR interval prolongation is prudent, particularly in patients with pre-existing conduction abnormalities.

Evidence-Based Rationale

FDA Warning Context

The FDA issued a warning about lamotrigine potentially causing cardiac rhythm and conduction abnormalities based on in vitro data showing Class IB antiarrhythmic effects 1. However, this warning has not been substantiated by robust clinical evidence.

Clinical Safety Data

Large population studies demonstrate safety:

• A Danish cohort of 91,949 lamotrigine users found no increased risk of cardiac conduction disorders in patients without pre-existing cardiac disease (adjusted HR 1.03,95% CI 0.76-1.40) 2
• Among 5,180 users with pre-existing cardiac disease, there was no increased all-cause mortality (adjusted HR 1.05,95% CI 0.93-1.19) 2
• A systematic review of >3,054 participants found insufficient evidence to support the breadth of the FDA warning 3

Electrophysiologic effects are minimal:

• Lamotrigine causes a modest, nonpathological 3.1% increase in PR interval (atrioventricular conduction time) 4
• This PR prolongation occurs equally in patients with and without heart disease (3.5% vs 2.8% increase) 4
• Critically, lamotrigine is not associated with increased odds of clinically pathological PR, QRS, or QTc prolongation 4
• Each 1 μg/mL increase in serum concentration associates with only a 2.3% PR interval increase 4

Congenital Heart Disease-Specific Considerations

No specific contraindications exist in CHD guidelines:

• The 2024 ESC AF guidelines address multiple drug considerations in congenital heart disease but do not list lamotrigine as contraindicated 5
• The 2018 AHA/ACC/HRS guidelines for ventricular arrhythmias in congenital heart disease focus on Class IC antiarrhythmics (flecainide, propafenone) and amiodarone as potentially harmful for prophylactic use, but do not mention lamotrigine 6

Structural heart disease does not increase risk:

• In a veteran population study with 87.5% having cardiac diagnoses, only 7.1% showed potential EKG abnormalities (using permissive criteria), with no cardiac deaths attributed to lamotrigine 7
• The presence of structural heart disease in the recent research showed increased VT incidence but this was in bipolar/epilepsy populations, not specifically CHD 8

Clinical Approach

When prescribing lamotrigine in CHD patients:

1. Baseline assessment:

   • Obtain baseline ECG focusing on PR interval, QRS duration, and QTc
   • Document any pre-existing conduction abnormalities (first-degree AV block, bundle branch blocks)
   • Review for concomitant sodium channel blocking medications

2. Monitoring strategy:

   • Repeat ECG after reaching therapeutic dose (typically 200-400 mg/day)
   • Monitor for PR interval changes >20% from baseline
   • No routine monitoring needed if baseline ECG normal and patient asymptomatic

3. High-risk scenarios requiring closer monitoring:

   • Pre-existing first-degree AV block (PR >200 ms)
   • Concomitant use of other sodium channel blockers (Class IC antiarrhythmics)
   • Complex CHD with prior arrhythmia history
   • Fontan physiology or systemic right ventricle

4. Dose considerations:

   • Use standard dosing protocols
   • No dose reduction required solely based on CHD diagnosis
   • Consider therapeutic drug monitoring if concerns arise

Important Caveats

Avoid conflating different cardiac populations:

• The FDA warning and some research focused on acquired heart disease, not congenital heart disease specifically
• Ventricular arrhythmia data from bipolar/epilepsy populations 8 may not directly apply to CHD patients without these conditions

Drug interactions matter more than CHD itself:

• Concomitant sodium channel blockers (flecainide, propafenone) may have additive effects
• Beta-blockers commonly used in CHD (recommended for complex CHD with frequent VA 6) do not contraindicate lamotrigine use

The evidence gap:

• No studies specifically examined lamotrigine safety in isolated CHD populations
• Extrapolation from general cardiac disease populations suggests safety, but CHD-specific data would be ideal